PROCTER & GAMBLE HEALTH | RAYMED LABS | PROCTER & GAMBLE HEALTH/ RAYMED LABS |
|||
---|---|---|---|---|---|
P/E (TTM) | x | 34.6 | -7.7 | - | View Chart |
P/BV | x | 10.6 | - | - | View Chart |
Dividend Yield | % | 2.0 | 0.0 | - |
PROCTER & GAMBLE HEALTH RAYMED LABS |
EQUITY SHARE DATA | |||||
---|---|---|---|---|---|
PROCTER & GAMBLE HEALTH Jun-23 |
RAYMED LABS Mar-23 |
PROCTER & GAMBLE HEALTH/ RAYMED LABS |
5-Yr Chart Click to enlarge
|
||
High | Rs | 5,366 | 2 | 263,019.6% | |
Low | Rs | 3,883 | 1 | 260,604.0% | |
Sales per share (Unadj.) | Rs | 740.7 | 0 | - | |
Earnings per share (Unadj.) | Rs | 138.2 | -0.4 | -34,518.3% | |
Cash flow per share (Unadj.) | Rs | 155.2 | -0.4 | -40,154.2% | |
Dividends per share (Unadj.) | Rs | 95.00 | 0 | - | |
Avg Dividend yield | % | 2.1 | 0 | - | |
Book value per share (Unadj.) | Rs | 447.6 | -5.4 | -8,288.5% | |
Shares outstanding (eoy) | m | 16.60 | 4.27 | 388.8% | |
Bonus / Rights / Conversions | 0 | 0 | - | ||
Price / Sales ratio | x | 6.2 | 0 | - | |
Avg P/E ratio | x | 33.5 | -4.4 | -758.4% | |
P/CF ratio (eoy) | x | 29.8 | -4.6 | -653.9% | |
Price / Book Value ratio | x | 10.3 | -0.3 | -3,158.4% | |
Dividend payout | % | 68.7 | 0 | - | |
Avg Mkt Cap | Rs m | 76,761 | 8 | 1,017,707.7% | |
No. of employees | `000 | NA | NA | - | |
Total wages/salary | Rs m | 2,062 | 0 | 542,552.6% | |
Avg. sales/employee | Rs Th | 0 | 0 | - | |
Avg. wages/employee | Rs Th | 0 | 0 | - | |
Avg. net profit/employee | Rs Th | 0 | 0 | - |
INCOME DATA | |||||
---|---|---|---|---|---|
Net Sales | Rs m | 12,296 | 0 | - | |
Other income | Rs m | 184 | 0 | 87,571.4% | |
Total revenues | Rs m | 12,480 | 0 | 5,942,904.8% | |
Gross profit | Rs m | 3,247 | -2 | -174,559.1% | |
Depreciation | Rs m | 281 | 0 | 562,000.0% | |
Interest | Rs m | 8 | 0 | - | |
Profit before tax | Rs m | 3,142 | -2 | -183,742.7% | |
Minority Interest | Rs m | 0 | 0 | - | |
Prior Period Items | Rs m | 0 | 0 | - | |
Extraordinary Inc (Exp) | Rs m | 0 | 0 | - | |
Tax | Rs m | 847 | 0 | - | |
Profit after tax | Rs m | 2,295 | -2 | -134,193.0% | |
Gross profit margin | % | 26.4 | 0 | - | |
Effective tax rate | % | 27.0 | 0 | - | |
Net profit margin | % | 18.7 | 0 | - |
BALANCE SHEET DATA | |||||
---|---|---|---|---|---|
Current assets | Rs m | 11,713 | 0 | 23,425,600.0% | |
Current liabilities | Rs m | 6,791 | 1 | 754,533.3% | |
Net working cap to sales | % | 40.0 | 0 | - | |
Current ratio | x | 1.7 | 0.1 | 3,104.6% | |
Inventory Days | Days | 263 | 0 | - | |
Debtors Days | Days | 343 | 0 | - | |
Net fixed assets | Rs m | 10,617 | 2 | 703,106.0% | |
Share capital | Rs m | 166 | 43 | 388.4% | |
"Free" reserves | Rs m | 7,265 | -66 | -11,042.0% | |
Net worth | Rs m | 7,431 | -23 | -32,222.5% | |
Long term debt | Rs m | 0 | 0 | - | |
Total assets | Rs m | 22,330 | 2 | 1,431,391.0% | |
Interest coverage | x | 409.1 | 0 | - | |
Debt to equity ratio | x | 0 | 0 | - | |
Sales to assets ratio | x | 0.6 | 0 | - | |
Return on assets | % | 10.3 | -109.5 | -9.4% | |
Return on equity | % | 30.9 | 7.4 | 416.6% | |
Return on capital | % | 42.4 | 7.4 | 572.3% | |
Exports to sales | % | 0 | 0 | - | |
Imports to sales | % | 13.1 | 0 | - | |
Exports (fob) | Rs m | NA | NA | - | |
Imports (cif) | Rs m | 1,605 | NA | - | |
Fx inflow | Rs m | 1,465 | 0 | - | |
Fx outflow | Rs m | 1,605 | 0 | - | |
Net fx | Rs m | -140 | 0 | - |
CASH FLOW | |||||
---|---|---|---|---|---|
From Operations | Rs m | 2,360 | -2 | -143,902.4% | |
From Investments | Rs m | -215 | 2 | -13,109.8% | |
From Financial Activity | Rs m | -985 | NA | - | |
Net Cashflow | Rs m | 1,160 | 0 | - |
Indian Promoters | % | 0.0 | 28.4 | - | |
Foreign collaborators | % | 51.8 | 0.0 | - | |
Indian inst/Mut Fund | % | 20.0 | 1.0 | 2,080.2% | |
FIIs | % | 6.2 | 0.0 | - | |
ADR/GDR | % | 0.0 | 0.0 | - | |
Free float | % | 48.2 | 71.6 | 67.3% | |
Shareholders | 56,778 | 1,504 | 3,775.1% | ||
Pledged promoter(s) holding | % | 0.0 | 0.0 | - |
Compare PROCTER & GAMBLE HEALTH With: DIVIS LABORATORIES CIPLA SUN PHARMA DR. REDDYS LAB ZYDUS LIFESCIENCES
No comparison is complete without understanding how the stock prices have performed over a period of time.
Here's a brief comparison:
Period | Procter & Gamble Health | RAYMED LABS. | S&P BSE HEALTHCARE |
---|---|---|---|
1-Day | -0.43% | 0.00% | 0.45% |
1-Month | -1.15% | 9.63% | 2.55% |
1-Year | 0.73% | 17.16% | 56.14% |
3-Year CAGR | -8.76% | 36.97% | 15.22% |
5-Year CAGR | 4.97% | -0.08% | 19.63% |
* Compound Annual Growth Rate
Here are more details on the Procter & Gamble Health share price and the RAYMED LABS. share price.
Moving on to shareholding structures...
The promoters of Procter & Gamble Health hold a 51.8% stake in the company. In case of RAYMED LABS. the stake stands at 28.4%.
To review how promoter stakes have changed over time, and how much of the promoter stake is pledged, please see the shareholding pattern of Procter & Gamble Health and the shareholding pattern of RAYMED LABS..
Finally, a word on dividends...
In the most recent financial year, Procter & Gamble Health paid a dividend of Rs 95.0 per share. This amounted to a Dividend Payout ratio of 68.7%.
RAYMED LABS. paid Rs 0.0, and its dividend payout ratio stood at -0.0%.
You may visit here to review the dividend history of Procter & Gamble Health, and the dividend history of RAYMED LABS..
For a sector overview, read our pharmaceuticals sector report.
After opening the day on high, Indian share markets reversed the trend as the session progressed and ended the lower.